Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Université Laval

$25,000.00

Analytical methods and analysis of in vivo toxicology of nanoparticles derived from the papaya-mosaic virus.

EF 2017-18

Résumé
Folia Biotech is a clinical-stage nanomedicine company working in the field of immunotherapy usingnanoparticles derived from papaya mosaic virus. En route toward clinical validation of their platformtechnology, they require further information on the blood circulation profile and biodistribution of their leadproduct.This proposal will be divided into two parts: 1) establishing a robust labeling method allowing tracking of theirnanoparticles in complex biological samples and 2) evaluating the circulation and biodistribution profiles oftheir proprietary technology. Together, these objectives will allow Folia to acquire the methods necessary tofurther understand how their nanoparticle interact with biological environments. This project will offertechnical knowledge and fundamental toxicology understanding. This will create value surrounding theproprietary technology, and foster the interest of pharmaceutical companies for collaborations.The academic lab involved in this project possesses accredited excellence in the labelling of nanoparticles andthe evaluation of their circulation profiles. By advancing the development of a nanomedicine technology thatcan be used for vaccination and immunotherapy, this project will create value for Canada, and contribute to thetraining of highly qualified personnel.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
515286-2017
Name nom
Bertrand, Nicolas
Department département
Pharmacie, Faculté de
Organization id
51
Institution établissement
Université Laval
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Analytical methods and analysis of in vivo toxicology of nanoparticles derived from the papaya-mosaic virus.
Keyword
NSERC
Application summary
Folia Biotech is a clinical-stage nanomedicine company working in the field of immunotherapy usingnanoparticles derived from papaya mosaic virus. En route toward clinical validation of their platformtechnology, they require further information on the blood circulation profile and biodistribution of their leadproduct.This proposal will be divided into two parts: 1) establishing a robust labeling method allowing tracking of theirnanoparticles in complex biological samples and 2) evaluating the circulation and biodistribution profiles oftheir proprietary technology. Together, these objectives will allow Folia to acquire the methods necessary tofurther understand how their nanoparticle interact with biological environments. This project will offertechnical knowledge and fundamental toxicology understanding. This will create value surrounding theproprietary technology, and foster the interest of pharmaceutical companies for collaborations.The academic lab involved in this project possesses accredited excellence in the labelling of nanoparticles andthe evaluation of their circulation profiles. By advancing the development of a nanomedicine technology thatcan be used for vaccination and immunotherapy, this project will create value for Canada, and contribute to thetraining of highly qualified personnel.